Virchow: The Largest Foundation Model for Computational Pathology To Date
Aiming to develop a single model to detect cancer, including rare cancers
Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
Aiming to develop a single model to detect cancer, including rare cancers
Findings from E1910 study
Enzalutamide Viatris is a generic of Xtandi, which has been authorised in the EU since 2013
Findings from the ETER701 study
Findings from a phase Ib/II study
Evidence for efficacy is based on the results from the Study E1910 and Study 20120215
Findings from the LUMINOSITY study
It is intended for the first-line treatment of patients who are candidates for systemic therapy, followed by maintenance treatment
Evidence for efficacy is based on the results from the EPCORE NHL-1 study
Findings from the EVOKE-01 study
Findings from the ESCORT-NEO/NCCES01 study
Findings from the ScreenTrustMRI study
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.